Menü Kapat

Urotoxicity and safety data of low-dose intravenous cyclophosphamide therapy for rheumatic diseases: A Single-Center retrospective cohort study

Orjinal Article

Urotoxicity and safety data of low-dose intravenous cyclophosphamide therapy or rheumatic diseases: A Single-Center retrospective cohort study

Receiving Date: 07 March 2022

Accept Date: 21 May 2022

Available Online: 20.06.2022

doi: 10.5455/medscience.2022.03.055

Medicine Science 2022;11(3):1003-6

Conflict of interests: The authors declare that there is no conflict of interest in the study.
Financial Disclosure: The authors declare that they have received no financial support for the study.
Ethical approval: The study was approved by the X University Institutional Review Board and Ethics Committee (Project no: KA21/74) and supported by the Başkent University Research Fund.

Table 1. Patients' demographic, clinical and laboratory data

 3,434 total views,  20 views today

Tufan MA, Tekkarismaz N, Dalgic GS, Yucel AE. Urotoxicity and safety data of low-dose intravenous cyclophosphamide therapy for rheumatic diseases: A Single-Center retrospective cohort study
. Med Science. 2022;11(3):1003-6.

⇓ PlumX Meter

Corresponding Author:Muge Aydin Tufan, Baskent University Faculty of Medicine, Department of Rheumatology, Adana, Turkey.
E-mail: mugeaydin@yahoo.com